Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

Core Points - Portage Biotech, Inc. has received notification from Nasdaq that its compliance plan has been accepted, granting an extension to meet continued listing standards [1][2] - The minimum shareholders' equity required is $2.5 million, or alternatively, a market value of listed securities of at least $35 million or net income from continued operations of at least $500,000 in the most recent fiscal year or in two of the last three completed fiscal years [1] - Nasdaq will review Portage's adherence to the compliance plan periodically, with a deadline set for June 9, 2025, to regain compliance [2] Company Overview - Portage Biotech is a clinical-stage immuno-oncology company focused on developing novel biologics to enhance the immune system's ability to combat cancer [3]